<DOC>
	<DOCNO>NCT02586935</DOCNO>
	<brief_summary>This study examine safety efficacy tideglusib vs. placebo treatment core symptom domains adolescent Autism Spectrum Disorders</brief_summary>
	<brief_title>Tideglusib v . Placebo Treatment Adolescents With Autism Spectrum Disorders</brief_title>
	<detailed_description>There pharmacologic treatment available social function deficit individual Autism Spectrum Disorders ( ASD ) . The data pharmacologic treatment repetitive behaviour disorder also become difficult interpret give last two large multisite trial selective serotonin re-uptake inhibitor ( SSRIs ) autism report negative treatment repetitive behaviour . Only associated symptom irritability 2 drug Food Drug Administration ( FDA ) indication , whereas systematic data exist pharmacologic treatment anxiety ASD , response rate stimulants hyperactivity low see Attention Deficit Hyperactivity Disorder ( ADHD ) . In addition , biological marker treatment response identify population point . This study examine potential efficacy safety tideglusib core associate symptom domains autism , explore biological marker safety treatment response . As juvenile toxicity publish animal model , limit age range 12 year age old .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>1 . Outpatients 1217 year age inclusive mental age equivalent ≥ 18 month Screening . 2 . Weigh minimum 30 kg ( 3rd percentile 12 year age ) 3 . Meet Diagnostic Statistical Manual Mental Disorders . Diagnostic Statistical Manual ( DSM5 ) criterion establish clinician expertise individual ASD . 4 . Have Clinician 's Global ImpressionSeverity ( CGIS ) score ≥ 4 ( moderately ill ) Screening . 5 . If already receive stable concomitant medication affect behaviour , stable regimen change precede 1 month prior Screening ( exception fluoxetine , period 6 week need ) , electively initiate new modify ongoing medication duration study 6 . If already receive stable nonpharmacological educational behavioural intervention , continuous participation precede 3 month prior Screening , electively initiate new modify ongoing intervention duration study 7 . Have normal physical examination laboratory test result Screening . If abnormal , find ( ) must deem clinically insignificant Investigator . 8 . Ability obtain write informed consent participant , developmentally appropriate . If participant capacity consent , ability obtain assent ( developmentally appropriate ) , well write inform consent parent ( ) /legal guardian . 1 . Patients primary psychiatric diagnosis ASD 2 . Pregnant female patient ; sexually active female patient inadequate birth control . 3 . Patients known phosphatase tensin homolog ( PTEN ) mutation unlikely respond medication 4 . Patients serious medical condition , base Investigator judgment , might interfere conduct study , confound interpretation study result , endanger wellbeing . Patients evidence significant hematological , endocrine , cardiovascular ( include uncorrected symptomatic congenital heart disease ) , respiratory , renal , hepatic , gastrointestinal disease , include mild common pediatric disease area stable ( e.g . mild asthma , constipation , etc. ) . 5 . Patients unstable epilepsy ( i.e . seizure occur within last 6 month ) , patient epilepsy stable dos antiepileptic medication ( i.e . dose change within last 3 month ) . 6 . Patients hypersensitivity tideglusib component formulation . 7 . Patients unable tolerate venipuncture procedure blood sample . 8 . Patients actively enrol another intervention study . 9 . Patients elevate liver enzyme ≥ 3 time normal amount study begin . 10 . Patients serum creatinine &gt; 150 μmol/L creatinine clearance ≤60ml/m ( accord CockcroftGault formula ) Screening . 11 . Patients take strong CYP3A4 inhibitor ( e.g . clarithromycin , telithromycin , ketoconazole , itraconazole , posaconazole , nefazodone , indinavir , ritonavir ) 12 . Inability speak understand English sufficiently enough allow completion study assessment ( parent ; patient , verbal ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ASD</keyword>
	<keyword>Autism</keyword>
</DOC>